LSIF invests in AcouSort

Life Science Invest Fund with a 6% stake in the company becomes the largest single shareholder in AcouSort AB.
AcouSort AB is an innovative technology company based in Lund focusing on developing products and solutions for integrated preparation of biological samples. Using ultrasound, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples in a fast and gentle way. With the help of the company's products and development of point of care tests, new diagnostic systems and treatments are enabled.
AcouSort AB is well underway with the transformation from an R&D company to a commercial enterprise, and we expect the company to double its revenue in 2025 and become cash flow positive in 2027/2028.
With a very modest market capitalization at the moment, we consider the company a good match for our portfolio with significant upside potential within the next 3 years.